Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Long-term Objective C  

$2,302,240.00
Fiscal Year: 2010

Green dot: Objective has greater than or equal to the recommended funding.4LC. Conduct at least one study to evaluate the safety and effectiveness of medications commonly used in the treatment of co-occurring conditions or specific behavioral issues in people with ASD by 2015. IACC Recommended Budget: $10,000,000 over 5 years.

Download 2010 Question 4: Long-term Objective C projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders McDougle, Christopher Indiana University
Pharmacotherapy of pervasive developmental disorders Stigler, Kimberly Indiana University-Purdue University Indianapolis
Targeted pharmacologic interventions for autism McDougle, Christopher Indiana University-Purdue University Indianapolis
1/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD McDougle, Christopher Indiana University-Purdue University Indianapolis
2/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD King, Bryan Seattle Children's Hospital
3/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD McCracken, James University of California, Los Angeles
4/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD Scahill, Lawrence Yale University